<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692185</url>
  </required_header>
  <id_info>
    <org_study_id>#5116 (MH069868-02)</org_study_id>
    <secondary_id>1R21MH069868-01</secondary_id>
    <secondary_id>DSIR A2-AID</secondary_id>
    <nct_id>NCT00692185</nct_id>
  </id_info>
  <brief_title>Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa</brief_title>
  <official_title>Atypical Antipsychotic Medication in Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of the antipsychotic medication olanzapine in
      treating outpatients with anorexia nervosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anorexia nervosa (AN) is a disease of disordered eating and is characterized by
      self-starvation, extreme weight loss, and difficulty maintaining a normal weight. Symptoms
      and behaviors of AN may include distorted body image, obsessive exercise, lack of
      menstruation among women, binge and purge eating behaviors, and intense fear of weight gain.
      Furthermore, people with AN are at a high risk of other mental disorders, such as depression
      and anxiety, and medical complications, such as organ damage, heart failure, and
      osteoporosis. Current treatments for AN include nutrition counseling, psychotherapy, and
      medication. Although weight restoration is a treatment priority, no particular therapeutic
      approach for patients with AN has clear empirical support. Previous studies have suggested
      that certain medications usually used to treat schizophrenia, also known as atypical
      antipsychotic drugs, may be helpful in increasing appetite and reducing anxiety related to
      weight gain and eating in people with AN. Specifically, the atypical antipsychotic
      medication olanzapine may be effective in improving overall symptoms of AN and in restoring
      weight to normal levels. This study will compare the effectiveness of the antipsychotic
      medication olanzapine versus placebo in treating outpatients with AN.

      Participation in this study will last 8 weeks. All participants will first undergo baseline
      assessments that will include questionnaires and interviews about AN symptoms, a physical
      exam, vital sign measurements, an electrocardiograph (EKG), and a blood draw. Participants
      will then be assigned randomly to 8 weeks of daily treatment with olanzapine or placebo.
      Participants will meet with a study doctor weekly over the 8 weeks of treatment. During
      these visits, the study doctor will monitor participants' progress, medication dosage, vital
      signs, and side effects. Participants will also fill out weekly questionnaires about the
      status of their condition and monthly repeat baseline questionnaires. In addition,
      participants will undergo blood draws every 2 weeks for the first month of the study and
      every 4 weeks for the remainder of the study. Upon completing the 8 weeks of treatment,
      participants will repeat the baseline assessments. During the next 5 years, participants may
      be contacted to complete a follow-up interview.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weight Gain</measure>
    <time_frame>Measured at Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Measured at Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Eating Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take olanzapine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria (not including amenorrhea) for AN

          -  Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2

          -  Patient (or family if the patient is a minor) refuses hospitalization

          -  Free of psychotropic medication (4 weeks medication free for fluoxetine and
             antipsychotic medication; 2 weeks medication free for all others) OR on a stable dose
             of an SSRI or SNRI (venlafaxine) for 4 weeks before study entry

          -  Prior treatment of AN

        Exclusion Criteria:

          -  Any medical or psychiatric problem requiring urgent attention and/or any significant
             comorbid illness not likely to benefit from proposed treatments

          -  Allergy to olanzapine

          -  Significant orthostatic high blood pressure

          -  Recent commencement of psychotherapy in the community

          -  Diabetes mellitus, with a fasting serum glucose greater than 120 mg/dL or nonfasting
             serum glucose greater than 140 mg/dL

          -  Known history of current or past jaundice

          -  Known history of narrow angle glaucoma

          -  Active substance abuse or dependence

          -  Schizophrenia, schizophreniform disorder, or bipolar illness

          -  Movement disorder or presence of tics

          -  History of tardive dyskinesia

          -  History of seizures

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Attia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute at Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eating Disorders Clinic, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2008</firstreceived_date>
  <firstreceived_results_date>May 28, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anorexia Nervosa</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Eating Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>Dosing of olanzapine began at 2.5 mg daily and was increased every two weeks, first to 5 mg, then 10 mg if the patient was tolerating the medication. If side effects were significant, dosage of the study medication could be lowered. All subjects recieved 16 weeks of assigned medication.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take matched placebo for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>Dosing of olanzapine began at 2.5 mg daily and was increased every two weeks, first to 5 mg, then 10 mg if the patient was tolerating the medication. If side effects were significant, dosage of the study medication could be lowered. All subjects recieved 16 weeks of assigned medication.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take matched placebo for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28.6" spread="9.9"/>
                <measurement group_id="B2" value="26.9" spread="8.7"/>
                <measurement group_id="B3" value="27.7" spread="9.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight Gain</title>
        <time_frame>Measured at Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Dosing of olanzapine began at 2.5 mg daily and was increased every two weeks, first to 5 mg, then 10 mg if the patient was tolerating the medication. If side effects were significant, dosage of the study medication could be lowered. All subjects recieved 16 weeks of assigned medication.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take matched placebo for 16 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Weight Gain</title>
            <units>lbs</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.2" spread="6.6"/>
                  <measurement group_id="O2" value="1.5" spread="4.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <time_frame>Measured at Week 8</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Dosing of olanzapine began at 2.5 mg daily and was increased every two weeks, first to 5 mg, then 10 mg if the patient was tolerating the medication. If side effects were significant, dosage of the study medication could be lowered. All subjects recieved 16 weeks of assigned medication.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take matched placebo for 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Evelyn Attia, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>212-543-5923</phone>
      <email>ea12@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
